Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Resmed (RMD)

robot
Abstract generation in progress

Analysts from Barclays and KeyBanc have issued bullish ratings for Merck & Company (MRK) and Resmed (RMD), respectively. Barclays analyst Emily Field gave Merck a Buy rating with a $140.00 price target, while KeyBanc analyst Brett Fishbin maintained a Buy rating on Resmed. Both stocks show significant upside potential according to analyst consensus price targets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin